Aspen bags Covid-19 vaccine deal with Johnson & Johnson
Agreement will enable drugmaker to use spare manufacturing capacity and bring down overhead costs, says CEO
02 November 2020 - 10:44
UPDATED 02 November 2020 - 15:37
SA’s biggest pharmaceutical manufacturer, Aspen Pharmacare, has signed a preliminary agreement to produce the candidate Covid-19 vaccine being developed by US drugmaker Johnson & Johnson (J&J) at its Port Elizabeth site, it announced on Monday.
The news was cheered by shareholders, who boosted Aspen’s share price by up to 11.5% in intraday trading, its biggest daily gain since April 18. Its share price closed at R117.65, its highest since October 1...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.